Koers Shanghai Pharmaceuticals Holding Co., Ltd Other OTC
Aandelen
SHPMY
US81943R1005
Farmaceutische producten
Omzet 2024 * | 288 mld. 39,86 mld. 36,73 mld. | Omzet 2025 * | 317 mld. 43,79 mld. 40,36 mld. | Marktkapitalisatie | 61,19 mld. 8,45 mld. 7,79 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 4,83 mld. 667 mln. 615 mln. | Nettowinst (verlies) 2025 * | 5,84 mld. 807 mln. 744 mln. | EV/omzet 2024 * | 0,26 x |
Nettoschuld 2024 * | 13,27 mld. 1,83 mld. 1,69 mld. | Nettoschuld 2025 * | 19,41 mld. 2,68 mld. 2,47 mld. | EV/omzet 2025 * | 0,25 x |
K/w-verhouding 2024 * |
12,5
x | K/w-verhouding 2025 * |
11,3
x | Werknemers | - |
Dividendrendement 2024 * |
3,07% | Dividendrendement 2025 * |
3,48% | Vrij verhandelbaar | 38,5% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yong Zhong Li
PSD | President | 54 | 27-06-19 |
Bo Shen
PSD | President | 51 | 05-06-13 |
Ye Lu
IRC | Investor Relations Contact | 35 | 01-01-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bo Shen
PSD | President | 51 | 05-06-13 |
Yong Zhong Li
PSD | President | 54 | 27-06-19 |
Manson Fok
BRD | Director/Board Member | 67 | 27-06-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+19,31% | 73,31 mld. | |
-4,75% | 23,98 mld. | |
+4,89% | 8,8 mld. | |
-20,79% | 8,07 mld. | |
-1,41% | 4,16 mld. | |
+12,27% | 4,14 mld. | |
-2,75% | 3,88 mld. | |
+23,24% | 3,72 mld. | |
-0,77% | 3,04 mld. |